Last week, we were excited to announce the nomination of our first smart GIP/GLP-1 pancreatic gene therapy lead candidate, RJVA-002, which is designed for the treatment of obesity. RJVA-002 is a ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

TUESDAY, Nov. 12, 2024 (HealthDay News) — For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors ...

The oral presentation "Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves ... to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced ... for synergistic use with GLP-1s, and for maintenance to ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

GLP-1 drugs not only promote weight loss, they’ve also been shown to help lower blood pressure and decrease the formation of ...

Bushnell also noted the ability of GLP-1 receptor agonists to decrease blood pressure and to decrease plaque formation associated with atherosclerosis, which is a risk factor for heart attack and ...

Conditions are getting a bit more challenging for the drugmaker.